Stanford Cancer Institute

Cancer Cell Therapy

Non-Hodgkins Lymphoma

- Relapsed or refractory disease after CD19-directed therapy
- Relapsed or refractory disease third-line

Diffused Large B-Cell Lymphoma

≥ 18 Yrs

CCT0529
Phase I/II
Autologous CD22 CAR T-Cells in Adults w/ Recurrent or Refractory B-Cell Malignancies

CCT0562
Phase I/II
bbT369 Dual Targeting CAR T-Cell Drug Product w/ Gene Edit in Relapsed and/or Refractory B-Cell NHL, PI: Ganjoo Sponsor: SevenBio Inc., Priority: 2nd

CCT0541
Phase I
Anti-CD70 CRISPR-Cas9-Engineered T-Cells (CTX130) in Relapsed/Refractory T/B-Cell Malignancies

CCT0501
Phase I CD19/CD22 Chimeric Antigen Receptor (CAR) T-Cells in Recurrent/Refractory B-Cell Malignancies

CCT0516
Managed Access Program (MAP) CTL019 in ALL or DLBCL

PI: Miklos Sponsor: Novartis

CCT0504
Phase II
Allo-501 (Anti-CD19 Allogeneic CAR T-Cell Tx) in Relapsed/Refractory Large B-Cell Lymphoma

PI: Parveen Sponsor: Kite Pharma

CCT0524
Phase II
Axicabtagene Ciloleucel +/- Rituximab or Lenalidomide in Refractory Large B-Cell Lymphoma

PI: Miklos Allogene

Priority: 1st

CCT0532
Phase II
Axicabtagene Ciloleucel +/- Rituximab or Lenalidomide in Refractory Large B-Cell Lymphoma

PI: Miklos Allogene

Priority: 2nd

CCT0543
Phase II
Allo-501A (Anti-CD19 Allogeneic CAR T-Cell Tx) in Relapsed/Refractory Large B-Cell Lymphoma

PI: Miklos Allogene

Priority: 3rd

**KEY**

- Pending
- Open for Enrollment
- Observational Study
- Link
- Trial Posting
- Optional Path
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu